New hope for advanced cancer patients as yale tests experimental drug
NCT ID NCT07027488
Summary
This is the first study in humans testing a new drug called AB821 for people with advanced melanoma and other solid tumors that have spread. The main goal is to find a safe dose and understand how the drug works in the body. Researchers will also check if the drug helps shrink tumors in patients whose cancer has progressed after standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Yale University
RECRUITINGNew Haven, Connecticut, 06510, United States
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.